Temperature-stable TB vaccine safe

Temperature-stable TB vaccine safe

A temperature-stable TB vaccine has been proven safe and prompts an immune response according to an NIH-supported study

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.

The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

A non-temperature stable form of the candidate previously had been tested in several clinical trials. However, this was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) form.

The experimental vaccine, ID93+GLA-SE, was developed by Christopher B Fox, PhD, and scientists at the Access to Advanced Health Institute (formerly the Infectious Disease Research Institute) in Seattle, USA.

It is a recombinant subunit vaccine made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant.

The freeze-dried formulation does not require refrigeration and is mixed with sterile water just prior to injection. Thermostable vaccines are desirable in settings where maintaining cold or frozen vaccines for long periods can be costly and difficult.

See also: Tuberculosis vaccine does not protect elderly from Covid-19

 

Safe and well-tolerated

 

The current trial investigated whether administering temperature-stable vaccine containing both ID93 and GLA-SE in a single vial would be as effective at inducing an immune response as a regimen in which non-thermostable ID93 and liquid GLA-SE are held in two vials and combined prior to injection.

A single-vial presentation of a thermostable vaccine would have clear advantages in ease of storage, transport and administration, the investigators note.

Daniel F Hoft, MD, director of the Saint Louis University Center for Vaccine Development, led the single-site trial at the university’s School of Medicine.

Twenty-three participants received the thermostable single-vial regimen, while 22 participants received the two-vial, non-thermostable regimen.

Both vaccine presentations were safe and well-tolerated.

Recipients of the single-vialled thermostable vaccine had robust T-cell responses and produced higher levels of antibodies in the blood than those receiving the non-thermostable two-vial presentation. 

The investigators note some limitations in this small trial.

For example, no established correlates of protection define what immune responses are required for vaccine-induced protection from TB disease. Therefore, it is not possible to say whether the enhanced immune responses seen in the thermostable vaccine formulation would translate to improved protective vaccine efficacy.

Nevertheless, they conclude, results of this trial demonstrate: “a proof-of-concept that adjuvant-containing vaccines can be formulated in a freeze-dried single-vial presentation without detrimentally impacting clinical immunogenicity or safety characteristics.” 

The results are published in Nature Communications.

Image: Scanning electron micrograph of Mycobacterium tuberculosis bacteria, which cause TB. © NIAID. Public domain.

Leave a reply

Your email address will not be published. Required fields are marked *

Aether: Issue 3 Feb 2023

Aether: Issue 2 Nov 2022

Aether: Issue 1 Aug 2022

Subscribe for free

Latest Testimonial

What a beautiful motto: Discoveries must be read and not just published. When I was contacted by Aether as a new digital service to share scientific and technological insights I had my doubts that this was really going to be according to what I call the “open source & makers’ spirit”: knowledge should be free and it is there to be shared.

Well, Aether is faithful to its motto and shares discoveries freely. It has been a pleasure to collaborate for the interview and subsequent article. It has been greatly self satisfying to see how the interview was professionally and truthfully redacted and then published. Sharing thoughts and sparks for discussions is fundamental to the progress of society. Your journal offers clarity and brevity and I believe it provides the sparks to ignite any reader whether academic or not into action.

Dr Maria-Cristina Ciocci
Co-founder and Manager of non-profit organisation De Creative STEM,GirlsInSTEM